Literature DB >> 10386651

Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy.

B Pickett1, E Vigneault, J Kurhanewicz, L Verhey, M Roach.   

Abstract

PURPOSE/
OBJECTIVE: Recent studies supported by histopathological correlation suggest that the combined use of endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) allows differentiation of normal and carcinomatous prostate. The goal of this study was to use static field intensity modulated three-dimensional conformal radiotherapy (SF-IMRT) to treat the entire prostate to a total dose of >70 Gy, while concurrently treating a dominant intraprostatic lesion (DIL) defined by MRI+MRS to 90 Gy while not exceeding normal tissue tolerances.
MATERIALS AND METHODS: For the example chosen, the DIL consisted of a large portion of the peripheral zone of the left lobe of the prostate. University of Michigan (UM-PLAN) three-dimensional treatment planning software was used to design a partially shielded 7 field conformal isodose plan that would treat the entire prostate to >70 Gy at 1.8 Gy per day (80% isodose line), while concurrently treating the DIL to 2.25 Gy per day for a total dose of 90 Gy. Dose volume histograms (DVH) were used to compare the rectal doses to rectum and other adjacent normal tissues using these two techniques.
RESULTS: SF-IMRT as described, allowed a total dose of 90 Gy to encompass the DIL, while the rectal dose was slightly lower than that using the standard 7 field technique to the prostate alone. For example, the dose to 30 cm3 of the rectum was 40 Gy using SF-IMRT and 48 Gy for the standard 7 field technique. Because of differences in the dose per fraction the biologic advantages of the SF-IMRT technique are likely to be even greater.
CONCLUSIONS: This study demonstrates the feasibility of using SF-IMRT to treat a DIL involving a single lobe of the prostate, as defined by MRI/MRS, to 90 Gy, while simultaneously treating the prostate to >70 Gy without increasing the dose to surrounding normal tissues. A similar approach could be used to treat multifocal disease. This method of treatment is an alternative to dynamic intensity modulation. It is less expensive, and can be adapted to any radiation therapy department without the use of an inverse treatment planning programs.

Entities:  

Mesh:

Year:  1999        PMID: 10386651     DOI: 10.1016/s0360-3016(98)00502-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  33 in total

Review 1.  The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy.

Authors:  L C Costello; R B Franklin
Journal:  Oncology       Date:  2000-11       Impact factor: 2.935

2.  On the impact of functional imaging accuracy on selective boosting IMRT.

Authors:  Y Kim; W A Tomé
Journal:  Phys Med       Date:  2008-01-18       Impact factor: 2.685

3.  Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans.

Authors:  Yusung Kim; Wolfgang A Tome
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

Review 4.  70 Gy or more: which dose for which prostate cancer?

Authors:  U Ganswindt; F Paulsen; A G Anastasiadis; A Stenzl; M Bamberg; C Belka
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-11       Impact factor: 4.553

5.  Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis.

Authors:  Cher Heng Tan; Wei Wei; Valen Johnson; Vikas Kundra
Journal:  AJR Am J Roentgenol       Date:  2012-10       Impact factor: 3.959

6.  Therapeutic Strategies for Localized Prostate Cancer II: Perineal Prostatectomy, X-Rays, Protons, Neutrons, and Combination Brachytherapy.

Authors:  M D Weil; A T Porter; D C Beyer; P S Albert; D Chinn; M J Harris
Journal:  Rev Urol       Date:  2000

7.  Dosimetric benefit of DMLC tracking for conventional and sub-volume boosted prostate intensity-modulated arc radiotherapy.

Authors:  Tobias Pommer; Marianne Falk; Per R Poulsen; Paul J Keall; Ricky T O'Brien; Peter Meidahl Petersen; Per Munck af Rosenschöld
Journal:  Phys Med Biol       Date:  2013-03-14       Impact factor: 3.609

8.  Choline PET based dose-painting in prostate cancer--modelling of dose effects.

Authors:  Maximilian Niyazi; Peter Bartenstein; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2010-03-18       Impact factor: 3.481

9.  MRI-guided HDR prostate brachytherapy in standard 1.5T scanner.

Authors:  Cynthia Ménard; Robert C Susil; Peter Choyke; Gary S Gustafson; William Kammerer; Holly Ning; Robert W Miller; Karen L Ullman; Nancy Sears Crouse; Sharon Smith; Etienne Lessard; Jean Pouliot; Victor Wright; Elliot McVeigh; C Norman Coleman; Kevin Camphausen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-08-01       Impact factor: 7.038

Review 10.  Advances in MR spectroscopy of the prostate.

Authors:  John Kurhanewicz; Daniel B Vigneron
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.